Edition:
United States

BIOLASE Inc (BIOL.OQ)

BIOL.OQ on NASDAQ Stock Exchange Capital Market

0.43USD
16 Feb 2018
Change (% chg)

$-0.01 (-2.27%)
Prev Close
$0.44
Open
$0.43
Day's High
$0.46
Day's Low
$0.43
Volume
2,454
Avg. Vol
36,574
52-wk High
$1.57
52-wk Low
$0.32

Chart for

About

BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $34.21
Shares Outstanding(Mil.): 76.02
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 46.02 17.27
EPS (TTM): -- -- --
ROI: -- 9.08 35.43
ROE: -- 13.32 17.10

BRIEF-Dental Corporation Signs Letter Of Intent To Buy 3 Dental Clinics ‍​

* SIGNED LETTER OF INTENT TO BUY 3 DENTAL CLINICS WITH PRICE OF ABOUT 25 MILLION BAHT - 35 MILLION BAHT ‍​ Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Biolase Releases Statement‍ In Response To Cao Group Litigation​

* RELEASED STATEMENT‍ IN RESPONSE TO CAO GROUP LITIGATION​ Source text for Eikon: Further company coverage:

Jan 25 2018

BRIEF-CAO Group Filed Patent Infringement Lawsuits In Court Against Biolase

* CAO GROUP INC- FILED PATENT INFRINGEMENT LAWSUITS IN UNITED STATES DISTRICT COURT AGAINST BIOLASE INC Source text for Eikon: Further company coverage:

Jan 24 2018

BRIEF-Biolase Files For Possible Resale Of Up To 21.9 Mln Shares Of Common Stock By Selling Stockholders

* BIOLASE INC FILES FOR POSSIBLE RESALE OF UP TO 21.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - http://bit.ly/2Dj77iX Further company coverage:

Jan 16 2018

BRIEF-Dental Corporation posts qtrly ‍net profit of 12.4 mln baht

* Qtrly ‍ net profit 12.4 million baht versus 12.2 million baht Source text for Eikon: Further company coverage:

Nov 13 2017

BRIEF-Biolase announces commencement of rights offering

* Biolase announces commencement of rights offering Source text for Eikon: Further company coverage:

Nov 09 2017

BRIEF-Biolase reports Q3 non-GAAP loss per share $0.05

* Q3 revenue rose 18 percent to $10.8 million Source text for Eikon: Further company coverage:

Nov 01 2017

BRIEF-Biolase appoints Richard Lanman to board of directors

* Biolase - ‍Lanman replaces outgoing director Fredrick Moll​ Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-Biolase announces record date for previously announced proposed rights offering

* Biolase announces record date for previously announced proposed rights offering

Oct 30 2017

BRIEF-Biolase names John Beaver as Chief Financial Officer

* Biolase names John Beaver Senior Vice President, Chief Financial Officer Source text for Eikon: Further company coverage:

Oct 02 2017

Earnings vs. Estimates